The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

Table 4

Results obtained from comparison of cost-utility of two treatment methods for atrial fibrillation patients.

	Strategy	Cost (PPP$)	QALYs	Incremental cost	Incremental QALYs	ICER (incremental cost per QALY gained) PPP$
Cost-utility analysis (CUA)	Rivaroxaban	25275	0.5	0	0	Dominant
	Warfarin	26554	0.33	1279	-0.17	Dominated